MedTrace Logo

The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy

NCT04423406 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-04-21

No results posted yet for this study

Summary

150 selected patients will be recruited, who have at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or predominantly echolucent by standard ultrasonography. For each of the plaques, standard ultrasonography will be used to evaluate lesion echogenicity, while contrast-enhanced ultrasonography (CEUS) will be used to perform the visual and quantitative analysis of neovascularization. Each technique will be applied at baseline (at the time of study enrollment) and following 0.5、1 year of Elococumab Injection treatment. During the study, these patients will be treated with Elococumab Injection (1ml:140mg),ih, every two weeks.

Conditions

  • Carotid Artery Diseases

Sponsors & Collaborators

  • Zibo Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Bo Li · Zibo Central Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-12-31
Completion
2022-02-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04423406 on ClinicalTrials.gov